Literature DB >> 35980435

Prognostic factors of the synovial sarcoma of the extremities: imaging does matter.

Mickael Tordjman1, Charles Honoré2, Amandine Crombé3, Amine Bouhamama4, Antoine Feydy5, Laurent Dercle6, Leila Haddag7, Pierre-Alban Bouché8,9, Carine Ngo10, Axel Le Cesne11, Jean-Yves Blay12, Olivier Mir11, Mehdi Brahmi12, Charlotte Martin5, Marie Karanian13, Samy Ammari7, Michele Kind3, Virginie Audard14, François Le Loarer15, Behnam Rabiee16, Antoine Italiano17, Pascaline Boudou-Rouquette18, David Biau8, Corinne Balleyguier7, Frederique Larousserie14, Jean-Luc Drapé5, Fadila Mihoubi5.   

Abstract

OBJECTIVES: Synovial sarcomas (SS) of the extremities are rare soft tissue sarcomas that are more common in young adults. We deciphered the imaging phenotype of SS with the aim to determine if imaging could provide an incremental value to currently known prognostic factors (PF)-age and histological grade-to predict long-term overall survival (OS).
METHODS: This retrospective multicenter study included consecutive pediatric and adult patients with synovial sarcomas of the extremities from December 2002 to August 2020. Inclusion criteria were (i) a follow-up greater than 5 years and (ii) available pre-therapeutic MRI. A subset analysis included MRI and CT-scan. Clinical, pathological, and imaging variables were collected in all patients. The primary endpoint was to evaluate the association of these variables with OS using univariate and multivariate Cox regressions.
RESULTS: Out of 428 patients screened for eligibility, 98 patients (mean age: 37.1 ± 15.2 years) were included (MRI: n = 98/98, CT scan: n = 34/98; 35%). The median OS was 75.25 months (IQR = 55.50-109.12) and thirty-six patients (n = 36/98;37%) died during follow-up. The recurrence rate was 12.2% (n =12/98). SS lesions were mostly grade 2 (57/98; 58%). On MRI, SS had a mean long-axis diameter of 67.5 ± 38.3 mm. On CT scan, 44% (15/34) were calcified. Grade (hazard ratio [HR] = 2.71; 95%CI = 1.30-5.66; p = 0.008), size of the lesions evaluated on MRI (HR = 1.02; 95% CI = 1.01-1.03; p < 0.001), and calcifications on CT scan (HR = 0.10; 95% CI = 0.02-0.50; p = 0.005) were independent PF of OS.
CONCLUSIONS: This study demonstrated that imaging biomarkers can be used to predict long-term outcome in patients with SS. Strikingly, the presence of calcifications on CT scan is associated with favorable outcome and provides an incremental value over existing PF such as age, grade, and size. KEY POINTS: • Beyond its diagnostic value, MRI is a pre-operative prognostic tool in synovial sarcomas of the extremities since the size of the lesion is an important prognostic factor. • Calcifications on CT scans are independently and significantly associated with prolonged overall survival.
© 2022. The Author(s), under exclusive licence to European Society of Radiology.

Entities:  

Keywords:  Magnetic resonance imaging; Prognosis; Sarcoma

Year:  2022        PMID: 35980435     DOI: 10.1007/s00330-022-09049-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   7.034


  24 in total

Review 1.  Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts.

Authors:  Winette T A van der Graaf; Daniel Orbach; Ian R Judson; Andrea Ferrari
Journal:  Lancet Oncol       Date:  2017-03-02       Impact factor: 41.316

2.  Highly malignant soft tissue sarcoma of the extremity with a delayed diagnosis.

Authors:  Jong Hoon Park; Chang Ho Kang; Chul Hwan Kim; In Jung Chae; Ji Hun Park
Journal:  World J Surg Oncol       Date:  2010-09-23       Impact factor: 2.754

3.  Calcifying/ossifying synovial sarcoma: a clinicopathologic and molecular study of 5 cases.

Authors:  Nasir Ud Din; Amanda Hopkins; Aisha Memon; Zubair Ahmad; Rashida Ahmed
Journal:  Indian J Pathol Microbiol       Date:  2015 Jan-Mar       Impact factor: 0.740

4.  Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors.

Authors:  A H Krieg; F Hefti; B M Speth; G Jundt; L Guillou; U G Exner; A R von Hochstetter; M D Cserhati; B Fuchs; E Mouhsine; A Kaelin; F M Klenke; K A Siebenrock
Journal:  Ann Oncol       Date:  2010-08-17       Impact factor: 32.976

Review 5.  Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classification, and molecular mechanisms.

Authors:  C Sreekantaiah; M Ladanyi; E Rodriguez; R S Chaganti
Journal:  Am J Pathol       Date:  1994-06       Impact factor: 4.307

6.  Calcifying synovial sarcoma.

Authors:  J Varela-Duran; F M Enzinger
Journal:  Cancer       Date:  1982-07-15       Impact factor: 6.860

7.  MR imaging of myxofibrosarcoma and undifferentiated sarcoma with emphasis on tail sign; diagnostic and prognostic value.

Authors:  Hye Jin Yoo; Sung Hwan Hong; Yusuhn Kang; Ja-Young Choi; Kyung Chul Moon; Han-Soo Kim; Ilkyu Han; Minkyong Yi; Heung Sik Kang
Journal:  Eur Radiol       Date:  2014-06-03       Impact factor: 5.315

8.  Analysis of Margin Classification Systems for Assessing the Risk of Local Recurrence After Soft Tissue Sarcoma Resection.

Authors:  Kenneth R Gundle; Lisa Kafchinski; Sanjay Gupta; Anthony M Griffin; Brendan C Dickson; Peter W Chung; Charles N Catton; Brian O'Sullivan; Jay S Wunder; Peter C Ferguson
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

9.  Evaluation of conditional treatment effects of adjuvant treatments on patients with synovial sarcoma using Bayesian subgroup analysis.

Authors:  Sung Wook Seo; Jisoo Kim; Jihye Son; Sungbin Lim
Journal:  BMC Med Inform Decis Mak       Date:  2020-12-03       Impact factor: 2.796

10.  Synovial sarcoma of the extremities: prognostic factors for 20 nonmetastatic cases and a new histologic grading system with prognostic significance.

Authors:  André Mathias Baptista; Olavo Pires de Camargo; Alberto Tesconi Croci; Cláudia Regina G C M de Oliveira; Raymundo Soares de Azevedo Neto; Marcelo Abrantes Giannotti; Marcelo Tadeu Caiero; Telma Murias dos Santos; Márcia Datz Abadi
Journal:  Clinics (Sao Paulo)       Date:  2006-10       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.